GPT and metabolic dysfunction-associated steatohepatitis: In total, there were 935 middle-aged overweight or obese individuals with NAFLD or NASH (51% men; mean ± SD: age 49 ± 5 years; body mass index: 32 ± 3 kg/m2; serum aspartate aminotransferase (AST): 46 ± 28 UI/L; serum alanine aminotransferase (ALT): 62 ± 42 UI/L; proportion of known T2DM: 72.4%, and hemoglobin A1c level: 8.1 ± 0.6%), who were treated for a median of 26 weeks (inter-quartile range: 24–27 weeks).